TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30839090
Drug: DWt +
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWt + 400 mg/L of PLG
Study: 30839090
Drug: DWt +
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWt + 400 mg/L of LBS
Study: 21346110
Drug: Oral Fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Fat Tolerance Test (OFTT: 1 g lipid/kg body weight) followed by caffeinated coffee (5 mg/kg)
Study: 21346110
Drug: Caffeinated coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeinated coffee (5 mg/kg)
Study: 19233423
Drug: Oxybutynin chloride
Normalized name: Oxybutynin Chloride
DrugBank: Oxybutynin (DB01062)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxybutynin chloride topical gel (1 gm, 10% weight per weight, ethanol based formulation) once daily for 12 weeks
Study: 16391591
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (glucomannan and plant sterols)
Study: 1943932
Drug: Vitamin B1
Normalized name: Vitamin B1
DrugBank: Monophosphothiamine (DB16023)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B1 and/or diuretics treatment for alcohol-related cardiomyopathy
Study: 7005293
Drug: Flunisolide nasal
Normalized name: flunisolide nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunisolide nasal spray (300 micrograms/day or less)
Study: 10520573
Drug: Testosterone patches
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone patches (5 mg testosterone over 24 hours)
Study: 7669218
Drug: Fluoride-sucrose solution
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoride-sucrose solution (1 mg/kg, 5 mg/kg, 10 mg/kg)
Study: 7030902
Drug: Heptavax B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heptavax B vaccine (40 micrograms each, three doses)
Study: 7030902
Drug: Heptavax B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heptavax B vaccine
Study: 29156875
Drug: Dexamethasone (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.1 mg/kg IV 1 hour before anesthesia)
Study: 26529601
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g of calcium HMB for 8 weeks
Study: 15145964
Drug: St. John's
Normalized name: St. john's wort
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: St. John's wort (300 mg tablet, three times daily for 14 days)
Study: 10430427
Drug: Ropinirole (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropinirole (0.75 mg, titrated to a maximum of 24 mg)
Study: 10430427
Drug: Bromocriptine (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (1.25 mg, titrated to a maximum of 40 mg)
Study: 1646621
Drug: Ramipril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (5 mg) and felodipine ER (10 mg)
Study: 1646621
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Ramipril and Felodipine)
Study: 6950685
Drug: Cranial irradiation
Normalized name: geranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranial irradiation plus 5 doses of i.t. MTX
Study: 6950685
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of i.t. MTX after induction, repeated every 3 months
Study: 6950685
Drug: BCG therapy
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG therapy by scarification
Study: 29319497
Drug: Tigecycline plus
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tigecycline plus high-dose cefoperazone-sulbactam (1:1)
Study: 25101831
Drug: Simvastatin (SIM)
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin (SIM) lipid-based formulation in gelatin capsules coated with Eudragit® S100
Study: 25101831
Drug: Zocor® tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zocor® tablets (reference control)
Study: 25101831
Drug: Simvastatin (SIM)
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin (SIM) lipid-based formulation
Study: 24718367
Drug: Prasugrel 60-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 60-mg or 30-mg loading dose (LD)
Study: 24718367
Drug: Clopidogrel 600-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 600-mg loading dose (LD)
Study: 20598667
Drug: Sham group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham group patients who crossed over to 0.5 mg ranibizumab
Study: 20598667
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg ranibizumab after rollover to monthly dosing
Study: 20598667
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg ranibizumab after rollover to monthly dosing
Study: 12196219
Drug: One-visit treatment
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-visit treatment with gutta-percha and AH-26 sealer
Study: 12196219
Drug: Two-visit treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-visit treatment with calcium hydroxide for 4 weeks followed by gutta-percha and AH-26 sealer
Study: 9638715
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g of mannitol
Study: 9638715
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g of mannitol
Study: 2574051
Drug: SK&F 101468
Approvals — FDA: no, EMA: no, PMDA: no
Description: SK&F 101468 (doses between 80 micrograms and 2.5 mg)
Study: 2574051
Drug: SK&F 101468
Approvals — FDA: no, EMA: no, PMDA: no
Description: SK&F 101468 (up to 1 mg)
Study: 19149939
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human growth hormone (rhGH) 12 IU/d
Study: 9177418
Drug: Carbimazole plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbimazole plus low dose CT (Calsynar; 100 IU/day, 2 days/week)
Study: 9177418
Drug: Carbimazole plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbimazole plus high dose CT (Calsynar; 100 IU/day, 14 days/month)
Study: 8426767
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment for upper respiratory infections
Study: 3429867
Drug: AII/NA infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: AII/NA infusion
Study: 3429867
Drug: Dextrose/NA infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose/NA infusion
Study: 3429867
Drug: All/saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: All/saline infusion
Study: 3429867
Drug: Dextrose/saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose/saline infusion
Study: 17003850
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg exogenous melatonin orally
Study: 17003850
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg exogenous melatonin orally + CYP2C19 substrate
Study: 17003850
Drug: melatonin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: melatonin treatment
Study: 11277319
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate (MA) 480 mg/day during RT
Study: 9079231
Drug: NTG oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTG oral spray (Myocor Spray)
Study: 8421422
Drug: Three courses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three courses of cis-platinum containing chemotherapy
Study: 8421422
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment of surgery and postoperative radiotherapy
Study: 3784136
Drug: Topical forskolin
Normalized name: Coleus forskohlii root oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical forskolin (50 microliter of 1% forskolin)
Study: 3784136
Drug: Topical forskolin
Normalized name: Coleus forskohlii root oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical forskolin (two instillations)
Study: 3784136
Drug: Topical 0.25%
Normalized name: permethrin topical 0.25% topical kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.25% 1-timolol (pretreatment)
Study: 30112725
Drug: DFN-11 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: DFN-11 (3 mg sumatriptan injection)
Study: 27502706
Drug: Consensus-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consensus-based treatment
Study: 20156980
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual control (n = 15)
Study: 18551027
Drug: Ramipril treatment
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ramipril treatment group
Study: 16334717
Drug: External application
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: External application of Chinese drugs on acupoint Shenque (CV 8) combined with salpingostomy
Study: 22424890
Drug: Adverse events
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adverse events assessed using Young Mania Rating Scale (YMRS) and Systematic Assessment for Treatment Emergent effects (SAFTEE)
Study: 20439846
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of mexiletine 3 times daily
Study: 20439846
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of mexiletine 3 times daily
Study: 6092982
Drug: LoNaHCO3 dialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: LoNaHCO3 dialysis (sodium bicarbonate, Na = 134, HCO3 = 33 mEq/l)
Study: 6092982
Drug: HiNaAc dialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: HiNaAc dialysis (high sodium acetate, Na = 144, acetate = 33 mEq/l)
Study: 6092982
Drug: LoNaAc dialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: LoNaAc dialysis (sodium acetate, Na = 134, acetate = 33 mEq/l)
Study: 29664328
Drug: Monthly family
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly family expenditure
Study: 15625424
Drug: Infant formula
Normalized name: Infant formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infant formula with 0.8 g/100 ml GOS/FOS (OSF group)
Study: 9656585
Drug: 1 ml
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml of iodised oil (Lipiodol®) administered orally in Namentenga
Study: 9656585
Drug: 1 ml
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml of iodised oil (Lipiodol®) administered IM in Passore
Study: 7893024
Drug: Bupivacaine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (1 mg/kg of 0.5% bupivacaine with epinephrine 1:200000 in 20 mL of saline 0.9%)
Study: 7893024
Drug: Lidocaine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (3 mg/kg of 2% lidocaine with epinephrine in 20 mL of saline 0.9%)
Study: 7893024
Drug: Placebo (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (20 mL of saline 0.9%)
Study: 2505216
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg tobramycin solution, inhaled 3 times daily (15 patients)
Study: 2505216
Drug: 2 mL
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL saline, inhaled 3 times daily (12 patients)
Study: 21810191
Drug: Niacin (up
Normalized name: NIACIN (UPSHER-SMITH) 250MG SA TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niacin (up to 1,500 mg daily for 12 weeks)
Study: 19472972
Drug: Sequential bilateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential bilateral TKA under 1 anesthetic
Study: 11354235
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of sertraline
Study: 9442548
Drug: Sulpiride (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpiride (200 mg/day)
Study: 3107808
Drug: Total Parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total Parenteral Nutrition (TPN) and Enteral Feeding Program
Study: 29609566
Drug: Regular pulsatile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular pulsatile cupping with 8 treatments plus paracetamol on demand (n=37)
Study: 29609566
Drug: Minimal cupping
Normalized name: Centipeda minima whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal cupping with 8 treatments plus paracetamol on demand (n=36)
Study: 29609566
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with paracetamol on demand only (n=37)
Study: 29609566
Drug: Paracetamol intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol intake
Study: 26105516
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid jelly Inner Power(®) (IP) once daily for 21 days
Study: 25532503
Drug: Lafutidine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lafutidine (20 mg)
Study: 10853456
Drug: New endocrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: New endocrine agents for receptor-positive patients
Study: 6383779
Drug: Control (before
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (before therapy)
Study: 23234087
Drug: Active observation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active observation of dance therapy (30 min. live session)
Study: 9919039
Drug: Braun Oral‐B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Braun Oral‐B Interclean, model ID2
Study: 2210795
Drug: Preparation I
Normalized name: Wound Care Preparation Irrigation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation I (modified allergenic extract)
Study: 2210795
Drug: Preparation II
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation II (standard semi-depot extract)
Study: 31397126
Drug: Auricular-point pressure
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular-point pressure combined with personalized music therapy
Study: 27893933
Drug: Cancer and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cancer and Treatment Distress (CTXD) measure before transplantation and at 100 days and 180 days after HCT
Study: 17516149
Drug: Injectable insulin
Normalized name: insulin degludec Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable insulin
Study: 17516149
Drug: Current treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current treatment burden
Study: 15026583
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg leflunomide
Study: 15026583
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg leflunomide
Study: 31461581
Drug: 14 days
Normalized name: ponesimod
DrugBank: Ponesimod (DB12016)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 14 days of twice‐daily 16.5% Manuka honey + 1.3 mg/mL methylglyoxal sinonasal rinses and concurrent 10 days of placebo tablets (MH)
Study: 31461581
Drug: 14 days
Normalized name: ponesimod
DrugBank: Ponesimod (DB12016)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 14 days of twice‐daily saline sinonasal rinses and concurrent 10 days of culture‐directed antibiotic therapy (CON)
Study: 25599305
Drug: Intrathecal clonidine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal clonidine, 100 μg
Study: 14499421
Drug: Intrathecal adenosine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal adenosine, 2 mg
Study: 25599305
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (clonidine and adenosine)
Study: 16978994
Drug: Early invasive
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early invasive treatment strategy based on risk stratification
Study: 11003427
Drug: Injection technique
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection technique
Study: 3002786
Drug: Midazolam 0.1
Normalized name: midazolam 0.1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.1 mg kg‐1 and atropine 0.2‐0.4 mg i.m.
Study: 3002786
Drug: Papaveretum 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Papaveretum 0.4 mg kg‐1 and hyoscine 0.008 mg kg‐1 i.m.
Study: 26850709
Drug: Control (conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (conventional insulin pump therapy)
Study: 21865211
Drug: Natalizumab treatment
Normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Natalizumab treatment (monotherapy in AFFIRM)
Study: 21865211
Drug: Natalizumab treatment
Normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Natalizumab treatment (in combination with interferon β‐1a in SENTINEL)
Study: 21865211
Drug: Natalizumab treatment
Normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Natalizumab treatment (both alone and in combination with IFNβ)
Study: 20345732
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate (TU, Nebido(®)), 1,000 mg injected on day 1, followed by injections after 6 weeks and 18 weeks
Study: 11684917
Drug: Aspirin, beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin, beta blockers, and angiotensin-converting enzyme inhibitors
Study: 11684917
Drug: Reperfusion therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reperfusion therapy (thrombolysis and primary angioplasty)
Study: 9930483
Drug: Low-dose aprotinin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose aprotinin (n = 15)
Study: 9930483
Drug: High-dose aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose aprotinin (n = 16)
Study: 8040664
Drug: Gemcitabine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine at a dose of 1,000 mg/m2
Study: 8040664
Drug: Gemcitabine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine at a dose of 1,250 mg/m2
Study: 3051874
Drug: Prostaglandin vaginal
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostaglandin vaginal suppositories (PGE2)
Study: 28974069
Drug: Salbutamol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (200 µg)
Study: 19170659
Drug: Early surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early surfactant treatment (31 +/- 19 min)
Study: 19170659
Drug: Late surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late surfactant treatment (202 +/- 80 min)
Study: 15566454
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg elemental iron daily (n=55)
Study: 15566454
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg elemental iron weekly (n=56)
Study: 9283506
Drug: 65 mg
Normalized name: opium 65 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 65 mg of methadone
Study: 9283506
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg of buprenorphine
Study: 9283506
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of buprenorphine
Study: 9283506
Drug: Lower doses
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower doses of buprenorphine and methadone
Study: 24200186
Drug: Both NG
Normalized name: NG
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both NG and oral feeding
Study: 16689375
Drug: Beta-blocker carvedilol
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Beta-blocker carvedilol (5 mg/day)
Study: 16689375
Drug: Beta-blocker carvedilol
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Beta-blocker carvedilol (20 mg/day)
Study: 16689375
Drug: Beta-blocker carvedilol
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Beta-blocker carvedilol (under 2.5 mg/day)
Study: 12459688
Drug: Phenylephrine 100
Normalized name: phenylephrine 100 mcg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine 100 microg/ml
Study: 12459688
Drug: Ephedrine 3
Normalized name: ephedrine 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine 3 mg/ml
Study: 8306010
Drug: IVF treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVF treatment (1 or more cycles)
Study: 8306010
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (awaiting IVF treatment)
Study: 27842499
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of remifentanil (0.3‐μg/kg/min for 5 min followed by 0.1‐μg/kg/min)
Study: 27842499
Drug: Two bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two bolus injections of remifentanil (first bolus of 0.4 μg/kg and second bolus of 0.6 μg/kg after 3 min) and 0.1 μg/kg/min remifentanil
Study: 20386122
Drug: Treatment protocol
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment protocol (4RM parallel back half-squat)
Study: 16641287
Drug: Intranasal vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal vaccine with 7.5 microg hemagglutinin and 30 microg LTK63 with biovector
Study: 16641287
Drug: Intranasal vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal vaccine with 7.5 microg hemagglutinin and 30 microg LTK63 without biovector
Study: 16641287
Drug: Intramuscular vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular vaccine with 15 microg hemagglutinin and MF59 adjuvant
Study: 16641287
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (saline solution)
Study: 8667183
Drug: Fentanyl (0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (0.125 mg/70 kg i.v.)